The product is progressively resorbed by the body and replaced with natural breast tissue. Credit: Evonik

German additive manufacturing start-up BellaSeno has announced the signing of a long-term agreement for the use of speciality chemical company Evonik’s RESOMER bioresorbable polymer to create a new breast implant technology.

RESOMER will be used in BellaSeno’s 3D-printed Senella breast scaffold. The product is designed to be used after reconstruction, augmentation and revision surgery, and is progressively resorbed by the body and replaced with natural breast tissue.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This avoids the use of silicone implants and their associated complications such as capsular contracture, rupture and deflation. Patients will also be able to avoid going through the process of having their implants replaced every ten to 15 years, as is standard with most commercial types of breast implant.

Scaffolds will be available in multiple sizes and shapes to match the needs of individual patients.

First-in-human trials of Senella scaffolds with RESOMER are scheduled to commence in Germany before the end of 2019.

Evonik health care business line general manager Dr Jean-Luc Herbeaux said: “Evonik is pleased to be partnering with BellaSeno in the clinical development and commercialization of their innovative, 3D-printed breast implant technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Senella breast implant scaffolds can potentially enhance the quality of life of millions of patients worldwide who undertake surgical procedures each year. This agreement underlines the ability of Evonik to leverage the safety and versatility of RESOMER polymers, together with our advanced application technology services, to support customers in the commercialization of innovative medical devices.”

BellaSeno received ISO 113485 certification in July 2019, making it one of only a handful of companies worldwide to offer integrated contract additive manufacturing of implants under a medical device-specific quality standard.

BellaSeno co-founder and CEO Dr Simon Champ said: “BellaSeno GmbH is very excited to be working together with Evonik in this collaboration.”